Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, lived longer when treated with Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) in combination with GemOx. Safety of the combination appeared consistent with the known safety profiles of the individual medicines. The data will be submitted to health authorities and shared at an upcoming medical meeting.
Roche’s Columvi offers survival benefit in Phase III DLBCL trial
New biomarker may facilitate monitoring T1D patients™ healthIncrease in PD-1+ T-cells correlated with therapeutic response and less insulin use GdaÅ„sk, Poland “ 4 April 2024 “ PolTREG S.A. (Warsaw...
Pfizer`s blood cancer therapy Adcetris succeeds in late-stage trial
Pfizer`s Ruxience (rituximab) Receives Approval in Europe
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
Pfizer Inc`s Biologic Ruxience (Rituximab) Receives Approval in the U.S.
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
LONDON, July 26 (Reuters) - Obesity drugs will not join the World Health Organization's (WHO) latest essential medicines list, but treatments for diseases, including Ebola and multiple sclerosis will, documents published by the U.N. agency showed.
Dr Reddy's Laboratories on Wednesday said its biologics licence application for its proposed biosimilar rituximab candidate has been accepted for a substantive review by the US Food and Drug Administration (USFDA). This closely follows acceptance of the rituximab biosimilar dossier for review by two other regulatory agencies -- the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).nnnRead more at:nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-application-for-biosimilar-candidate-accepted-for-review-by-usfda/articleshow/101704158.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst